WINNIPEG, Feb. 19 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced a five-year research initiative to focus on the development and commercialization of MR-guided radiation therapy and interventional procedures, working with the University Health Network (UHN) in Toronto.
The collaboration signals the entry of IMRIS into the field of image guided radiation therapy, expanding on its existing expertise in neurosurgery. IMRIS, a market leader in the field of advanced surgical MR imaging and UHN, with its specialized knowledge in imaging and radiation therapy, will focus on the creation of innovative technologies for radiation therapy. The clinical setting for research and testing of technologies will be Princess Margaret Hospital (PMH), UHN's world-leading cancer research hospital. The IMRIS 3T movable MR will be installed at PMH to enable the development of new approaches to radiation therapy using active MR guidance.
The goals of the collaboration include the development of new technologies, the establishment of clinical workflows and the validation of the benefits of MR guided radiation therapy technology to both the patient and the health system. Planned applications include the integration of the IMRIS technology with external beam radiation therapy, MR guided biopsies and brachytherapy of the prostate.
Dr. David Jaffray, Head of Radiation Physics at PMH, said: "MR is a powerful, non-invasive imaging modality that enables us to better target disease and avoid healthy tissues. This is the future of cancer treatment and we're hoping that working with IMRIS will take us there faster."
"We are extremely pleased to be working with a recognized leader in cancer treatment and research," said David Graves President and CEO of IMRIS. "This co-development agreement represents a tremendous opportunity and opens an entirely new application for the existing IMRIS platform used in Neurosurgery today."
About Princess Margaret Hospital:
Princess Margaret Hospital has achieved an international reputation as a global leader in the fight against cancer and is considered one of the top comprehensive cancer treatment and research centres in the world. Located in Toronto, Canada, PMH is the only facility in Canada devoted exclusively to cancer research, treatment and education.
IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced surgical imaging solutions. The company's flagship product, IMRISneuro, utilizes patented technology that allows a high field MRI scanner to be moved in to the operating room on demand, providing imaging during the surgical procedure without compromising patient safety. This unique and innovative system has been validated by leading surgeons for use in world-class neuroscience centers.
For more information, visit www.imris.com
|SOURCE IMRIS Inc.|
Copyright©2009 PR Newswire.
All rights reserved